ProKidney Corp. is a late-clinical-stage biotechnology company developing autologous cell therapies to preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. Its lead product candidate, rilparencel, is a personalized therapy composed of Selected Renal Cells (SRC) isolated from a patient’s own kidney biopsy and reinjected into the kidneys to stabilize estimated glomerular filtration rate (eGFR). The company is currently conducting the Phase 3 REGEN-006 (PROACT 1) clinical trial in the United States, Mexico, and Taiwan, and has completed Phase 2 studies including REGEN-007. ProKidney operates a manufacturing facility in Winston-Salem, North Carolina, designed to comply with FDA and EMA quality standards for producing rilparencel. The technology provides an alternative to dialysis or kidney transplantation by addressing the loss of kidney function in patients with Stage 3b and 4 CKD.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage prokidney.com
Sector Healthcare IR page investors.prokidney.com
Tags
autologous cell therapy, chronic kidney disease, regenerative medicine, nephrology, personalized medicine, clinical stage, rilparencel, REGEN-006, PROACT 1, REGEN-007, RMCL-002, REGEN-003, REGEN-004, Selected Renal Cells, SRC
Press page —

Metrics

Valuation  
Market cap $ 501.839M
Market cap (USD) $ 501.839M
P/E -4.86
PEG —
P/BV -0.55
P/S 647.53
P/OCF -3.28
P/FCF -2.99
Dividend yield —
Turnover / mcap —
Returns  
ROE 6.8%
ROI —
ROIC —
Profit margin -7,725.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -46.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 893K 76K — —
Net profit -68.986M -61.186M -35.468M -148.135M
Free cash flow -135.313M -155.86M -124.266M -78.935M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 2.24 2.5 1.31 6.99
Price performance 12m -0.1 0.91 -0.81 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 1.33M 2.4M 4.41M 3.24M 4.04M
Cash and deposits (USD) 15.2M 4.58M 440,488 490M 60.6M 99.1M 109M
Intangible assets (USD) — — 428,000 213,000 0.00 — —
Right-of-use assets (USD) — — 1.14M 2.29M 4.12M 2.87M 3.59M
Cash flow detail
Operating cash flow (USD) — -25.2M -50.3M -77.1M -90.1M -126M -120M
Purchases of property, plant and equipment (USD) — -5.46M -5.19M -1.85M -34.2M -29.5M -15.2M
Change in payables (cash effect) (USD) — 683,000 7.87M 494,000 11.6M 11.6M -5.92M
Share buybacks (cash effect) (USD) — — 0.00 0.00 -9.5M 0.00 0.00
Income taxes paid (cash effect) (USD) — -145,000 -68,000 -1.95M -2.86M -73,000 -2.44M
Share-based compensation (USD) — 730,000 699,000 74.5M 30.8M 29.4M 25.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -30.6M -55.5M -78.9M -124M -156M -135M
Income detail
Research and development expense (USD) — 21M 46.3M 82.1M 107M 128M 114M
↳ 5y CAGR +40.2%
Total comprehensive income (USD) — — -55.1M -148M -135M -164M -152M
Comprehensive income to owners (USD) — — -55.1M -108M -35.3M -61.2M -69.1M
Reported Mar 28, 2023 Mar 28, 2023 Mar 22, 2024 Mar 22, 2024 Mar 22, 2024 Mar 17, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027

•Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by accelerated patient recruitment in mid-2026

•Presented eight abstracts at ASN Kidney Week 2026, with new data further strengthening the mechanistic and clinical evidence supporting rilparencel; subsequently hosted a KOL event recapping key ASN findings and rilparencel’s potential role in advanced CKD and type 2 diabetes

•Ended the third quarter with $142 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027

WINSTON-SALEM, N.C., November 12, 2026 – ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones.

The Company's cash and cash equivalents and marketable securities as of September 30, 2026 was $141.9 million.

Regulation FD Disclosure

ProKidney Corp. (the “Company”) has updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Presentation is available on the Company’s website at https://investors.prokidney.com/news-events/events-and-presentations. The Presentation is also attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 and Exhibit 99.1 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

On October 29, 2026, ProKidney Corp. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its Class A common stock, par value $0.0001 per share, through the Sales Agent, acting as agent. Pursuant to the Sales Agreement, sales of the Shares may be made by any method permitted that is deemed to be an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), in ordinary brokers’ transactions, to or through a market maker, on or through The Nasdaq Capital Market or any other market venue where the securities may be traded, in the over-the-counter market, in privately negotiated transactions or through a combination of any such methods of sale. Under the Sales Agreement, the Sales Agent will be entitled to compensation of up to 3.0% of the gross offering proceeds of all Shares sold through it pursuant to the Sales Agreement.

Prompts

ProKidney Corp. (ticker PROK), listed in United States.

Company History

Date Change Detail
Mar 17, 2022 Renamed SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III → PROKIDNEY CORP.

ETFs Holding ProKidney Corp.

ETF Weight in ETF Shares Market value As of
SURI 0.78% 483,741 $ 532.115K Nov 17, 2026
FSEG 0.06% 1,799 $ 3,669.96 Jun 30, 2026